The Ethical Minefield of Brain Enhancement: Who Gets Access and Who Gets Left Behind
Brain-computer interfaces promise to unlock human potential, but if history is any guide, that potential will be unlocked for some people far sooner than others.
Imagine a job interview in 2035. Your competitor for the role has a neural implant that sharpens working memory, accelerates information retrieval, and reduces cognitive fatigue. You don’t. Not because you chose not to, but because you couldn’t afford it. Who gets the job? More troubling still, who decides that question is even worth asking?
This isn’t a thought experiment ripped from science fiction. It’s the genuinely uncomfortable trajectory of a neurotech industry that, according to market projections tracked across multiple analyst reports, is expected to grow from $2.84 billion in 2024 to $11.2 billion by 2035. The broader neurotechnology sector may balloon from $15 billion to well over $58 billion across that same window. Money is pouring in. Ethics are limping behind. And the questions about who benefits, who governs, and who gets left holding nothing but a headache are getting louder.
To be fair, this field started in the right place. Brain-computer interfaces were originally conceived as tools for people who desperately needed them: patients with ALS, paralysis, locked-in syndrome, Parkinson’s disease. Blackrock Neurotech has enabled BCI users to type at up to 90 characters per minute using thought alone. Synchron’s endovascular device lets paralyzed patients send emails and control devices without a single hole drilled in the skull. These are real, meaningful breakthroughs for people with limited alternatives.
But the neurotech story does not end there. It never does. Elon Musk has stated openly that Neuralink’s long-term goal isn’t just treatment, it’s to “unlock human potential” in healthy people. And once that door opens even slightly, the ethical architecture gets a lot more complicated.
The rise of the neuroelite
There’s a term circulating in bioethics circles that deserves more airtime: “neuroelite.” It was used pointedly at a UNESCO Futures Dialogue in late 2025 to describe a class of wealthy individuals who might use neurotechnology not to treat illness, but to gain cognitive advantages unavailable to everyone else. One panelist called it “the Botox of the brain.” It’s a sharp analogy. And like Botox, it exposes something uncomfortable: when a technology is positioned as enhancement rather than treatment, it transforms from a medical tool into a consumer product. And consumer products have never been free. 🧠
The concern isn’t hypothetical. UNESCO’s own analysis of neurotechnology ethics explicitly warns that limiting advanced neurotech to the wealthy could widen existing social gaps and, in their words, “lead to social tensions and conflict.” Researchers publishing in the Balkan Medical Union journal in 2025 echoed the same worry, noting that unequal access to BCIs risks entrenching new forms of social division rather than erasing old ones.
What makes this particularly sharp is the speed of the gap’s potential widening:
An invasive neural implant currently requires surgery, neurological expertise, and ongoing clinical maintenance
Consumer-grade EEG headsets cost anywhere from a few hundred to several thousand dollars
The most capable devices, like Neuralink’s N1 chip, sit behind clinical trial walls with no public pricing
Wealthier nations are already ahead: the U.S. has over half of the world’s BCI recipients, per MIT Technology Review data 🔬
Think about your own reaction here: does the idea of a cognitive upper class strike you as distant and unlikely, or closer than comfortable? Share your honest answer in the comments, because how a community frames that question shapes what it demands from regulators.
The race dynamic makes this worse. China has formally designated brain-computer interfaces as one of seven strategic innovation areas, with multiple government ministries backing a five-year roadmap toward global BCI dominance by 2030. The U.S. response, largely private-sector-driven, has no equivalent coordinated equity mandate. A technology race between nations prioritizing strategic advantage rarely produces equitable distribution. 🌍
Your thoughts, their data
Set aside surgery for a moment. The subtler, more immediately urgent version of this problem is already in your living room.
Emotiv sells EEG earbuds for everyday use. Neurable ships headphones that monitor your cognitive load. Apple’s Vision Pro reportedly uses AI to infer emotional and attentional states from users’ biometric signals, according to former Apple Neurotechnology Prototyping Researcher Sterling Crispin. These are non-invasive, accessible, consumer-facing products, and they generate neural data at scale, right now.
Here is what makes that genuinely alarming rather than merely interesting: most existing privacy law was not built for this. Your credit card data, your location history, your browsing behavior are covered by a patchwork of regulations. But the electrochemical signature of your mental state? Until very recently, largely unaddressed. ⚡
That’s finally beginning to shift. A 2024 survey conducted across the U.S. found that the majority of Americans consider brain data at least as sensitive as genetic or financial data, and many are worried about corporate misuse. Courts and legislatures are starting to catch up:
California’s SB 1223 (signed September 2024) classifies neural data as “sensitive personal information” under the California Consumer Privacy Act
Minnesota went further, signing a law in May 2024 under Governor Tim Walz that includes criminal penalties for violations of neural data rights
Chile amended its constitution to protect “mental integrity” and ordered the deletion of brain data collected from a former senator
Brazil’s Rio Grande do Sul has enacted similar protections, and Mexico is advancing a constitutional amendment
These are meaningful steps. But they’re patchy, they’re territorial, and neurotech companies building products for global markets routinely exploit the gaps. MedCity News reported in December 2025 that neurotechnology “must be designed from the outset with audit trails, clear safety limits, and accountability,” calling out the failure to treat neural data governance the way it should be: exceptional, not merely routine. 🔐
Duke Law professor Nita Farahany, whose book The Battle for Your Brain has become essential reading in neuroethics, frames this as a right to cognitive liberty, the fundamental claim that individuals should control their own mental processes without surveillance or manipulation. She’s argued that cognitive liberty is a non-zero-sum right, meaning that protecting one person’s mental autonomy doesn’t subtract from anyone else’s. The problem is that without enforceable legal teeth, it stays a philosophical concept rather than a protection.
Regulations are running to catch up
In September 2025, Senators Chuck Schumer, Maria Cantwell, and Ed Markey announced the MIND Act, the Management of Individuals’ Neural Data Act. According to analysis from CSIS, it marks Congress’s first serious attempt to regulate the neurotech industry as neural data shifts from medical settings into consumer markets. The bill defines neural data as any information obtained by measuring activity of an individual’s central or peripheral nervous system, and frames cognitive biometric data as particularly sensitive because it can reveal mental states and emotions. 📋
That framing is exactly right. But legislation alone isn’t sufficient, for a few reasons that are worth naming clearly:
Regulation moves at policy speed; neurotech moves at VC speed. In 2025 alone, disclosed neurotech funding surpassed $1.3 billion, a figure tracked by NeurotechMag’s analysis of the sector’s tipping point signals
Regulatory frameworks distinguish poorly between therapeutic BCIs (helping the paralyzed walk or speak) and augmentative BCIs (making healthy brains faster). That distinction matters enormously for equity
The OECD’s Recommendation on Responsible Innovation in Neurotechnology, adopted by 39 countries, outlines nine principles but lacks binding enforcement mechanisms
Most regulatory bodies lack the neuroscience expertise to evaluate what they’re being asked to approve
The MIND Act, if passed in something close to its proposed form, would be a start. But history suggests that the gap between “start” and “sufficient” in technology regulation is very wide indeed. Social media had years of regulatory runway before meaningful oversight arrived, and the damage done in that interval was enormous. As MedCity News put it, the lesson is clear: neurotech should not repeat the mistakes of social media. 💡
A related problem researchers from PMC flagged in a 2025 paper is that existing oversight bodies, including Institutional Review Boards, were built to assess clinical research, not consumer or workplace applications of BCIs. The IEEE Neuroethics Framework offers more structured guidance, including evaluating ethical, legal, and sociocultural implications across use cases. But it’s voluntary, and voluntary frameworks in commercially lucrative spaces tend to get observed selectively.
What equitable access would actually require
Here’s where I think the discourse gets muddled. The equity conversation in neurotech often defaults to “we need more regulation,” which is true but incomplete. It also needs to include:
First, clinical trial diversity. If you look at who has received brain implants so far, roughly 75% of BCI recipients have been male, and more than half are in the United States. This matters because BCIs tuned primarily on one demographic’s neural data may not work as well on others. That’s not an abstract justice concern; it’s a concrete efficacy problem.
Second, a clinical-first sequencing rule. Several neuroethicists, including researchers publishing in Frontiers in Human Dynamics in 2025, have argued that augmentative BCIs should not be commercially available until therapeutic applications have proved effective, safe, and accessible across income levels. You shouldn’t be able to buy a cognition boost for $10,000 while people with ALS still can’t reliably access a communication implant. The sequencing matters. 🧬
Third, open-source and DIY neurotech as a legitimate access pathway. IEEE Spectrum has covered the emergence of DIY EEG platforms like PiEEG, available for around $250, that put BCI development within reach of researchers who aren’t backed by venture capital. Open-source hardware won’t deliver Neuralink-level performance, but it could lower the floor of access significantly. Treating open-source neurotech as a serious part of the equity solution rather than a hobbyist curiosity is a reframe worth making. 🔓
Fourth, children and adolescents need specific protections. UNESCO’s dialogue noted that children’s brains are not yet fully developed, which makes them more vulnerable to cognitive manipulation and neural data misuse, not less. Current frameworks largely address adult consumers. This is a gap that is not theoretical; it’s already relevant given the number of EEG-based attention tools marketed toward schools.
And fifth, international governance needs actual teeth. Chile’s constitutional amendment produced a court order to delete brain data. That’s accountability in action. The OECD’s soft-law approach hasn’t produced equivalent results anywhere. The Neurorights Foundation, led by Columbia neuroscientist Rafael Yuste, has been pushing hard for neurorights to be recognized in national constitutions globally, which would anchor them in a way that regulatory guidance simply cannot.
The question at the center of this
None of this is resolvable by any one actor. Not Neuralink, not the FDA, not UNESCO, not the MIND Act. What would actually change the trajectory is a sustained, public insistence that brain enhancement technology must be treated as a public good with access obligations, not a luxury product with charitable exceptions.
The comparison to vaccines is instructive. Society eventually decided that certain medical technologies were too consequential to distribute purely on market terms, and we built infrastructure to reflect that. The decision came slowly, imperfectly, and only after a lot of preventable harm. Whether neurotech takes the same slow path or a faster one depends significantly on how loudly and specifically the people who understand this field demand better.
Here’s the question I’d leave you with: If cognitive enhancement became widely available and genuinely effective in the next decade, would you want access regulated as a right or priced as a product? And do you think the industry, as it’s currently structured, would get to the answer you prefer on its own? 🧠
The stakes aren’t small. They’re the architecture of what human potential means, and who gets to develop it.